NCT05017246 2025-07-31
Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural Anesthesia With Postoperative PCA for Patients Undergoing Exploratory Laparotomy
Washington University School of Medicine
Phase 2 Terminated
Clinical Trials
17 trialsNCT03194646 2025-07-28
ASTEROID 6
Bayer
Phase 3 Terminated
NCT02209545 2023-09-07
Misoprostol for Reduction of Blood Loss During Fibroid Surgery
Northwestern University
Phase 4 Terminated
NCT03400943 2023-05-03
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)
Bayer
Phase 3 Terminated
NCT03400956 2022-06-30
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)
Bayer
Phase 3 Terminated
NCT02811159 2019-06-27
An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Terminated
NCT00730886 2018-08-15
ExAblate Treatment of Uterine Fibroids for Fertility Enhancement
InSightec
Phase NA Terminated
NCT01842789 2017-08-18
TAG
Acessa Health, Inc.
Phase NA Terminated
NCT01555073 2016-07-28
Preemptive Analgesia Following Uterine Artery Embolization
Northwestern University
Phase 4 Terminated
NCT01675011 2016-03-11
Embozene Microspheres for Uterine Fibroid Embolization (UFE)
Boston Scientific Corporation
Phase NA Terminated
NCT00958893 2014-08-25
An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext
Repros Therapeutics Inc.
Phase 2 Terminated
NCT00683917 2014-08-21
Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Terminated
NCT00737282 2014-08-21
Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT00785356 2014-08-21
Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT00853567 2014-08-21
Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT01069120 2014-08-21
Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT00496080 2012-09-10
DUAO
Ethicon, Inc.
Phase NA Terminated